Receive The Newest Study Notifications

Pulmatrix, Inc. (NASDAQ: PULM) announces today that three sites in the United States have been activated for the Phase 2 clinical investigation for Pulmazole (PUR1900) – an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the treatment of...

- Aerie Pharmaceuticals, Inc.(NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases...

A new study has applied machine-learning and statistical techniques to predict the outcomes of randomised clinical trials for new drug and device candidates. The research is a collaboration between the Massachusetts Institute of Technology (MIT) Laboratory for...

Dermata Therapeutics, LLC, today announces positive results from a Phase 1 POC clinical trial of DMT410 (DMT310 + botulinum toxin (BTX)) for the treatment of primary axillary hyperhidrosis. These results provide evidence of Dermata's newly developed combination...

Trial will evaluate safety and efficacy of onvansertib plus FOLFIRI and Avastin® (bevacizumab) for treatment of patients with KRAS-mutated metastatic Colorectal Cancer (mCRC) Highly recognized unmet need for 50% of mCRC patients who harbor the KRAS mutation, given...

- First patient dosed in Phase 3 trial evaluating efficacy and safety of maralixibat - Topline results expected in fourth quarter of 2020 Mirum Pharmaceuticals today announced the dosing of the first patient in the Phase 3 MARCH-PFIC clinical trial of its lead drug...

Tennessee’s innovative clinical trials network is soaring just one year into operations, bringing growing benefits for Tennesseans and the advancement of health care across the state. Launched in April 2018, the Clinical Trials Network of Tennessee (CTN2) has already...

Subcutaneous MarzAA (FVIIa) prophylaxis reduced the annualized bleeding rate by more than 90% compared with pretreatment Data presented at the 2019 Congress of the International Society on Thrombosis and Haemostasis Company to host investor call and webcast on Monday,...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN). VGX-3100 is an immunotherapy that targets human...

Vivacelle Bio, Inc. announces that the US Food and Drug Administration (FDA) has granted Dr. Cuthbert Simpkins, MD its Founder and Chief Innovation Officer, an Investigational New Drug (IND) clearance to proceed with a phase IIa clinical trial of the safety and...

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announced today that the first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal flu vaccine candidate have been successfully enrolled. Influenza viruses mutate...

300 mg Cohort of Phase 1b/2 Trial of Vecabrutinib now Enrolling Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the promotion of Judy Fox, Ph.D. from Chief Scientific Officer, Senior Vice President to Chief Scientific Officer, Executive Vice President,...

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today new clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA's platform immunotherapy targeting cancer stem cells. Blood...

Cyxone (publ), a Swedish biotech in autoimmune diseases, today submitted an application to the Central Ethics Committee (CEC) in Poland for permission to start a clinical phase IIb trial with its drug candidate Rabeximod, which is in development for the treatment of...

MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process CAMBRIDGE, Mass., July 8, 2019 /PRNewswire/ -- A new study published in the inaugural...

Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive...

BOSTON and SOPHIA ANTIPOLIS, France, July 8, 2019 /PRNewswire/ -- Median Technologies, The Imaging Phenomics Company® (ALMDT: PA) and AG Mednet have renewed their partnership to use AG Mednet's global infrastructure for the collection, QC and delivery of medical...

Collaboration Achieves First Significant Milestone with Successful Execution of Technology Transfer Additional Significant Milestones, Including Submission of the Investigational New Drug (IND) Application Which is Expected by the End of the Third Quarter TEL AVIV,...

Founders Fund-backed company announces 5 senior hires with domain experience from publicly traded companies including Veeva Systems, Salesforce, ICON and Munich Re Teckro, the company transforming clinical trials for the world's leading pharmaceutical and emerging...

Top-line Data Readout Remains on Track for early Q4 2019 Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases, today...